ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADMA BIOLOGICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$11.07+0.39 (+3.65%)

Close on Oct 19, 2026

Community

Notes and questions about Adma Biologics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Adma Biologics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADMA.

Revenue growth8.0% · median 19.6%

Gross margin64.7% · median 48.4%

Operating margin43.8% · median 11.4%

Net margin33.0% · median 5.3%

Advertisement
300 × 250